Columnist Patrick Moeschen argues that we all should focus more on finding the right words to accurately describe living with chronic illness.

A regimen of three immune-suppressing drugs may improve the effectiveness of gene therapy for people with DMD, research in ...

Upsher-Smith Laboratories launched DMD treatment Kymbee in the U.S., backed by a support program for patients.

Columnist Shalom Lim attended a musical honoring healthcare professionals and, as someone with Duchenne MD, came away feeling ...

Columnist Robin Stemple struggles to feel grateful on difficult days with FSHD, but still tries to recognize his many ...

Columnist Betty Vertin is planning a holiday season this year that will let her sons with DMD better enjoy their time with family and friends.

With three sons with Duchenne MD, columnist Betty Vertin has little time for housework, making her regret not giving the other kids chores.

A Phase 1/2 clinical trial testing SRP-1003 for myotonic dystrophy type 1 is progressing with higher doses as planned.

A Phase 1/2 clinical trial testing SRP-1003, a treatment for myotonic dystrophy type 1 (DM1), is progressing as planned and continues to enroll patients at higher doses. The Phase 1/2 study ...

What is Elevidys for Duchenne muscular dystrophy? Elevidys (delandistrogene moxeparvovec-rokl), previously known as SRP-9001, is a one-time gene therapy approved in the U.S. to treat patients with ...